With documented clonal evolution—spanning MM, (precursor) DCs, and ultimately pDC-AML—our case, involving two malignancies and somatic non-CHIP mutations (RUNX1, BCOR), supports evidence that MM may promote secondary myeloid malignancies independently of cytotoxic therapy. This evidence concerns the gene RUNX1 and Miyoshi myopathy.